Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Current Liabilities (2017 - 2025)

KalVista Pharmaceuticals' Total Current Liabilities history spans 11 years, with the latest figure at $45.2 million for Q2 2025.

  • On a quarterly basis, Total Current Liabilities rose 98.04% to $45.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was $45.2 million, a 98.04% increase, with the full-year FY2025 number at $45.2 million, up 98.04% from a year prior.
  • Total Current Liabilities hit $45.2 million in Q2 2025 for KalVista Pharmaceuticals, up from $26.1 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for KALV hit a ceiling of $45.2 million in Q2 2025 and a floor of $6.5 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $20.1 million across 4 years, with a median of $19.1 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: tumbled 33.23% in 2021 and later soared 98.04% in 2025.
  • Tracing KALV's Total Current Liabilities over 4 years: stood at $9.8 million in 2021, then skyrocketed by 81.61% to $17.8 million in 2023, then surged by 47.11% to $26.1 million in 2024, then soared by 72.96% to $45.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for KALV at $45.2 million in Q2 2025, $26.1 million in Q4 2024, and $22.2 million in Q4 2024.